Cargando…

Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques

BACKGROUND: Live attenuated simian immunodeficiency virus (SIV) vaccines represent the most effective means of vaccinating macaques against pathogenic SIV challenge. However, thus far, protection has been demonstrated to be more effective against homologous than heterologous strains. Immune correlat...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, Neil, Ham, Claire, Mee, Edward T., Rose, Nicola J., Mattiuzzo, Giada, Jenkins, Adrian, Page, Mark, Elsley, William, Robinson, Mark, Smith, Deborah, Ferguson, Deborah, Towers, Greg, Almond, Neil, Stebbings, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154277/
https://www.ncbi.nlm.nih.gov/pubmed/21853072
http://dx.doi.org/10.1371/journal.pone.0023092
_version_ 1782210000911859712
author Berry, Neil
Ham, Claire
Mee, Edward T.
Rose, Nicola J.
Mattiuzzo, Giada
Jenkins, Adrian
Page, Mark
Elsley, William
Robinson, Mark
Smith, Deborah
Ferguson, Deborah
Towers, Greg
Almond, Neil
Stebbings, Richard
author_facet Berry, Neil
Ham, Claire
Mee, Edward T.
Rose, Nicola J.
Mattiuzzo, Giada
Jenkins, Adrian
Page, Mark
Elsley, William
Robinson, Mark
Smith, Deborah
Ferguson, Deborah
Towers, Greg
Almond, Neil
Stebbings, Richard
author_sort Berry, Neil
collection PubMed
description BACKGROUND: Live attenuated simian immunodeficiency virus (SIV) vaccines represent the most effective means of vaccinating macaques against pathogenic SIV challenge. However, thus far, protection has been demonstrated to be more effective against homologous than heterologous strains. Immune correlates of vaccine-induced protection have also been difficult to identify, particularly those measurable in the peripheral circulation. METHODOLOGY/PRINCIPAL FINDINGS: Here we describe potent protection in 6 out of 8 Mauritian-derived cynomolgus macaques (MCM) against heterologous virus challenge with the pathogenic, uncloned SIVsmE660 viral stock following vaccination with live attenuated SIVmac251/C8. MCM provided a characterised host genetic background with limited Major Histocompatibility Complex (MHC) and TRIM5α allelic diversity. Early protection, observed as soon as 3 weeks post-vaccination, was comparable to that of 20 weeks vaccination. Recrudescence of vaccine virus was most pronounced in breakthrough cases where simultaneous identification of vaccine and challenge viruses by virus-specific PCR was indicative of active co-infection. Persistence of the vaccine virus in a range of lymphoid tissues was typified by a consistent level of SIV RNA positive cells in protected vaccinates. However, no association between MHC class I /II haplotype or TRIM5α polymorphism and study outcome was identified. CONCLUSION/SIGNIFICANCE: This SIV vaccine study, conducted in MHC-characterised MCM, demonstrated potent protection against the pathogenic, heterologous SIVsmE660 challenge stock after only 3 weeks vaccination. This level of protection against this viral stock by intravenous challenge has not been hitherto observed. The mechanism(s) of protection by vaccination with live attenuated SIV must account for the heterologous and early protection data described in this study, including those which relate to the innate immune system.
format Online
Article
Text
id pubmed-3154277
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31542772011-08-18 Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques Berry, Neil Ham, Claire Mee, Edward T. Rose, Nicola J. Mattiuzzo, Giada Jenkins, Adrian Page, Mark Elsley, William Robinson, Mark Smith, Deborah Ferguson, Deborah Towers, Greg Almond, Neil Stebbings, Richard PLoS One Research Article BACKGROUND: Live attenuated simian immunodeficiency virus (SIV) vaccines represent the most effective means of vaccinating macaques against pathogenic SIV challenge. However, thus far, protection has been demonstrated to be more effective against homologous than heterologous strains. Immune correlates of vaccine-induced protection have also been difficult to identify, particularly those measurable in the peripheral circulation. METHODOLOGY/PRINCIPAL FINDINGS: Here we describe potent protection in 6 out of 8 Mauritian-derived cynomolgus macaques (MCM) against heterologous virus challenge with the pathogenic, uncloned SIVsmE660 viral stock following vaccination with live attenuated SIVmac251/C8. MCM provided a characterised host genetic background with limited Major Histocompatibility Complex (MHC) and TRIM5α allelic diversity. Early protection, observed as soon as 3 weeks post-vaccination, was comparable to that of 20 weeks vaccination. Recrudescence of vaccine virus was most pronounced in breakthrough cases where simultaneous identification of vaccine and challenge viruses by virus-specific PCR was indicative of active co-infection. Persistence of the vaccine virus in a range of lymphoid tissues was typified by a consistent level of SIV RNA positive cells in protected vaccinates. However, no association between MHC class I /II haplotype or TRIM5α polymorphism and study outcome was identified. CONCLUSION/SIGNIFICANCE: This SIV vaccine study, conducted in MHC-characterised MCM, demonstrated potent protection against the pathogenic, heterologous SIVsmE660 challenge stock after only 3 weeks vaccination. This level of protection against this viral stock by intravenous challenge has not been hitherto observed. The mechanism(s) of protection by vaccination with live attenuated SIV must account for the heterologous and early protection data described in this study, including those which relate to the innate immune system. Public Library of Science 2011-08-10 /pmc/articles/PMC3154277/ /pubmed/21853072 http://dx.doi.org/10.1371/journal.pone.0023092 Text en Berry et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Berry, Neil
Ham, Claire
Mee, Edward T.
Rose, Nicola J.
Mattiuzzo, Giada
Jenkins, Adrian
Page, Mark
Elsley, William
Robinson, Mark
Smith, Deborah
Ferguson, Deborah
Towers, Greg
Almond, Neil
Stebbings, Richard
Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques
title Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques
title_full Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques
title_fullStr Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques
title_full_unstemmed Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques
title_short Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques
title_sort early potent protection against heterologous sivsme660 challenge following live attenuated siv vaccination in mauritian cynomolgus macaques
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154277/
https://www.ncbi.nlm.nih.gov/pubmed/21853072
http://dx.doi.org/10.1371/journal.pone.0023092
work_keys_str_mv AT berryneil earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT hamclaire earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT meeedwardt earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT rosenicolaj earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT mattiuzzogiada earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT jenkinsadrian earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT pagemark earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT elsleywilliam earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT robinsonmark earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT smithdeborah earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT fergusondeborah earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT towersgreg earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT almondneil earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques
AT stebbingsrichard earlypotentprotectionagainstheterologoussivsme660challengefollowingliveattenuatedsivvaccinationinmauritiancynomolgusmacaques